Search over 3,000 reports

    Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors - Competitive Landscape, Market and Pipeline Analysis 2017

    Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors - Competitive Landscape, Market and Pipeline Analysis 2017
    Date: Aug, 2017
    Type: Pharmaceutical
    Pages: 127
    Geography: Global
    Delivery Timeline: 24 Hours
    SKU: DISR0014

    DelveInsight's, "Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors – Competitive Landscape, Market and Pipeline Analysis 2017", report provides comprehensive insights about pipeline drugs across Cyclin Dependent Kinase 4/6 inhibitors. A key objective of the report is to establish the understanding for the therapeutic competitive landscape for this mechanism of action. It provides the marketed product details in this area. It also covers the pipeline drugs that fall under Cyclin Dependent Kinase 4/6 inhibitors including their comparative analysis at various stages covering Filed, Phase II, Phase I, Pre-clinical, and inactive products, therapeutics assessment by monotherapy and combination products and molecule type. The report also provides the market drivers and barriers for CDK 4/6 inhibitors.
    The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.
    Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

    Executive Summary
    Overview
    Marketed Drugs
    Pipeline Therapeutics
    Last Stage Products (Phase III)
    Mid Stage Products (Phase II)
    Early Stage Products (Phase I)
    Pre-clinical Stage Products
    Therapeutic Assessment: Active Products
    Inactive Products
    Market Drivers and Barriers
    Appendix

    Table 1: Active Pipeline Coverage by Indication
    Table 2: Total Products for Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitors
    Table 3: Late Stage Products (Filed)
    Table 4: Mid Stage Products (Phase II)
    Table 5: Early Stage Products (Phase I)
    Table 6: Pre-clinical Stage Products
    Table 7: Assessment by Monotherapy Products
    Table 8: Assessment by Route of Administration
    Table 9: Assessment by Stage and Route of Administration
    Table 10: Assessment by Stage and Molecule Type
    Table 11: Discontinued Products
    Table 12: Dormant Products

    Figure 1: Mechanism of Cyclin Dependent Kinase 4/6
    Figure 2: IBRANCE, Sales from 2015-2025 (in million USD)
    Figure 3: KISQALI, Forecasted Sales from 2017-2025 (in million USD)
    Figure 4: Patent Analysis
    Figure 5: Total Products for Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
    Figure 6: Late Stage Products (Filed)
    Figure 7: Abemaciclib, Forecasted Sales from 2018-2022 (in million USD)
    Figure 8: Mid Stage Products (Phase II)
    Figure 9: Early Stage Products (Phase I)
    Figure 10: Pre-clinical Stage Products
    Figure 11: Assessment by Monotherapy Products
    Figure 12: Assessment by Route of Administration
    Figure 13: Assessment by Stage and Route of Administration
    Figure 14: Assessment by Stage and Molecule Type
    Figure 15: Discontinued Products
    Figure 16: Dormant Products

    Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors Licensing opportunities

    Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors Market Drivers and Barriers

    SWOT Analysis

    Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors
    • Single User License
      $1,750.00
    • Site License
      $3,500.00
    • Global License
      $5,250.00

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap